Cancers, Vol. 15, Pages 2745: Efficacy and Safety of First-Line Cytokines Versus Sunitinib and Second-Line Axitinib for Patients with Metastatic Renal Cell Carcinoma (ESCAPE Study): A Phase III, Randomized, Sequential Open-Label Study

Conclusions: There was a trend toward better total PFS for IL-2 + IFNα, but it was not significant. There was also no advantage of IL-2 + IFNα in terms of OS. The study was underpowered to draw any definitive conclusions. The results showed no clear advantage of IL-2 + IFNα over sunitinib in the first-line setting; however, it may be an option in some relatively low-risk mRCC cases due to the difference in the AE profile. This trial was registered with the University Hospital Medical Information Network (UMIN), center identifier UMIN 000012522.

Source: Cancers - May 13, 2023 Category: Cancer & Oncology Authors: Yoshifumi Kadono Hiroyuki Konaka Takahiro Nohara Kouji Izumi Satoshi Anai Kiyohide Fujimoto Tomoyuki Koguchi Kei Ishibashi Noriyasu Kawai Keita Nakane Akinori Iba Naoya Masumori Shizuko Takahara Atsushi Mizokami Tags: Article Source Type: research